Product Pipeline

OUR MEDICINES IN DEVELOPMENT

Our priority is researching and developing medicines and vaccines that will benefit patients around the world. We are committed to addressing unmet needs across a number of important therapeutic areas including, Oncology, Inflammation & Immunology, Vaccines, Internal Medicine and Rare Disease, with the goal of delivering innovative products to patients. 

Key Innovative Programs

  • Abrocitinib - JAK1 Inhibitor: Atopic Dermatitis
  • Bavencio® (avelumab): Non-Small Cell Lung Cancer, Urothelial Cancer (in collaboration w/Merck KGaA)
  • Braftovi® (encorafinib) + Mektovi® (binimetinib)​: BRAF-mutant metastatic Colorectal Cancer, Melanoma, Non-Small Cell Lung Cancer
  • Duchenne Muscular Dystrophy Gene Therapy
  • fidanacogene elaparvovec (Coagulation Factor IX Gene Therapy): Hemophilia
  • giroctocogene fitelparvovec: Hemophilia Gene Therapy
  • Ibrance® (palbociclib): High Risk Early Breast Cancer, Early Breast Cancer in Adjuvant Setting, HER2+ Breast Cancer
  • Next Generation Pneumococcal Conjugate Prophylactic Vaccine: Invasive and Non-Invasive Pneumococcal Infections
  • Prophylactic Vaccine: Clostridioides difficile Infection
  • Ritlecitinib - JAK3/TEC Inhibitor: Alopecia Areata, Vitiligo
  • Talzenna® (talazoparib): Prostate Cancer
  • Tanezumab: Chronic Pain due to Moderate-to-Severe Osteoarthritis, Cancer Pain
  • Xeljanz® (tofacitinib): Ankylosing Spondylitis
  • Xtandi® (enzalutamide): Metastatic Hormone Sensitive Prostate Cancer, Non-Metastatic High Risk Hormone Sensitive Prostate Cancer

Pipeline Snapshot as of April 28, 2020

  • Discovery Projects
  • Phase 1
    27
  • Phase 2
    37
  • Phase 3
    21
  • Registration
    6
  • Total91
Therapeutic Area
Submission Type
Compound Type
Phase of Development
Compound NameIndicationPhaseSubmission TypeCompound Type
Daurismo (glasdegib)
Therapeutic Area:
Oncology
Phase:Registration
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
SMO (smoothened) antagonist
Combo w/low-dose cytarabine (LDAC) for Acute Myeloid Leukemia (E.U.) Registration New Molecular Entity Small Molecule
tanezumab
Therapeutic Area:
Internal Medicine
Phase:Registration
Compound Type:Biologic
Business Segment:
Biopharma
Mechanism of Action:
Nerve Growth Factor Inhibitor
Go to clinical trial
Chronic Pain due to Moderate-to-Severe Osteoarthritis (OA) (Biologic) (U.S., E.U.)
Project advanced
Registration New Molecular Entity Biologic
abrocitinib (PF-04965842)
Therapeutic Area:
Inflammation & Immunology
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
JAK Inhibitor
Go to clinical trial
Atopic Dermatitis (BREAKTHROUGH) Phase 3 New Molecular Entity Small Molecule
aztreonam-avibactam (PF-06947387)
Therapeutic Area:
Hospital (Anti-Infectives)
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
Beta Lactam/Beta Lactamase Inhibitor
Go to clinical trial
Treatment of infections caused by Gram-negative bacteria for which there are limited or no treatment options Phase 3 New Molecular Entity Small Molecule
fidanacogene elaparvovec (PF-06838435)
Therapeutic Area:
Rare Diseases
Phase:Phase 3
Compound Type:Biologic
Business Segment:
Biopharma
Mechanism of Action:
Gene Therapy, coagulation factor IX (F9)
Go to clinical trial
Hemophilia (Biologic) (BREAKTHROUGH, ORPHAN - U.S., E.U., PRIME - E.U.) Phase 3 New Molecular Entity Biologic
PF-06425090
Therapeutic Area:
Vaccines
Phase:Phase 3
Compound Type:Vaccine
Business Segment:
Biopharma
Mechanism of Action:
Prophylactic Vaccine
Go to clinical trial
Primary clostridioides difficile infection (FAST TRACK) Phase 3 New Molecular Entity Vaccine
PF-06482077
Therapeutic Area:
Vaccines
Phase:Phase 3
Compound Type:Vaccine
Business Segment:
Biopharma
Mechanism of Action:
Prophylactic Vaccine
Go to clinical trial
Invasive and Non-Invasive Pneumococcal infections (Adult) (BREAKTHROUGH) Phase 3 New Molecular Entity Vaccine
ritlecitinib (PF-06651600)
Therapeutic Area:
Inflammation & Immunology
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
JAK3/TEC
Go to clinical trial
Alopecia Areata (BREAKTHROUGH) Phase 3 New Molecular Entity Small Molecule
PF-06801591 + Bacillus Calmette-Guerin (BCG)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Biologic
Business Segment:
WRDM
Mechanism of Action:
Anti-PD-1
Go to clinical trial
Non-Muscle-Invasive Bladder Cancer (Biologic) Phase 3 New Molecular Entity Biologic
PF-07265803
Therapeutic Area:
Rare Diseases
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
p38 Mitogen-Activated Protein Kinase
Go to clinical trial
Dilated Cardiomyopathy due To Lamin A/C Gene Mutation Phase 3 New Molecular Entity Small Molecule
somatrogon (PF-06836922)
Therapeutic Area:
Rare Diseases
Phase:Phase 3
Compound Type:Biologic
Business Segment:
Biopharma
Mechanism of Action:
Human Growth Hormone Agonist
Go to clinical trial
Pediatric Growth Hormone Deficiency (Biologic) (ORPHAN - U.S., E.U.) Phase 3 New Molecular Entity Biologic
Dekavil
Therapeutic Area:
Inflammation & Immunology
Phase:Phase 2
Compound Type:Biologic
Business Segment:
WRDM
Mechanism of Action:
IL-10
Rheumatoid Arthritis (Biologic) Phase 2 New Molecular Entity Biologic
marstacimab (PF-06741086)
Therapeutic Area:
Rare Diseases
Phase:Phase 2
Compound Type:Biologic
Business Segment:
WRDM
Mechanism of Action:
Tissue Factor Pathway Inhibitor (TFPI)
Hemophilia (Biologic) (FAST TRACK - U.S.; ORPHAN - U.S., E.U.) Phase 2 New Molecular Entity Biologic
PF-05221304
Therapeutic Area:
Internal Medicine
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
Acetyl CoA-Carboxylase (ACC) Inhibitor
Non-Alcoholic Steatohepatitis (NASH) with Liver Fibrosis (FAST TRACK) Phase 2 New Molecular Entity Small Molecule
PF-06480605
Therapeutic Area:
Inflammation & Immunology
Phase:Phase 2
Compound Type:Biologic
Business Segment:
WRDM
Mechanism of Action:
TNFSF15 Blocker
Ulcerative Colitis (Biologic) Phase 2 New Molecular Entity Biologic
PF-06650833
Therapeutic Area:
Inflammation & Immunology
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
IRAK4
Rheumatoid Arthritis Phase 2 New Molecular Entity Small Molecule
ritlecitinib (PF-06651600) / brepocitinib (PF-06700841)
Therapeutic Area:
Inflammation & Immunology
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
Biopharma
Mechanism of Action:
JAK3/TEC; TYK2/JAK1
Ulcerative Colitis Phase 2 New Molecular Entity Small Molecule
brepocitinib (PF-06700841)
Therapeutic Area:
Inflammation & Immunology
Phase:Phase 2
Compound Type:Small Molecule
Business Segment:
WRDM
Mechanism of Action:
Topical TYK2/JAK1
Atopic Dermatitis Phase 2 New Molecular Entity Small Molecule